---
title: "Morgan Stanley lowered the target price for WuXi XDC to 86 yuan, rating it as \"Overweight.\""
description: "Morgan Stanley has lowered the target price for WUXI XDC to 86 yuan, with a rating of \"Overweight.\" Due to a decline in operating profit margins, the bank has reduced its earnings forecast for 2026 to"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276404577.md"
published_at: "2026-02-20T02:19:47.000Z"
---

# Morgan Stanley lowered the target price for WuXi XDC to 86 yuan, rating it as "Overweight."

> Morgan Stanley has lowered the target price for WUXI XDC to 86 yuan, with a rating of "Overweight." Due to a decline in operating profit margins, the bank has reduced its earnings forecast for 2026 to 2030 by 1% to 2%. Nevertheless, it is expected that WUXI XDC's adjusted net profit compound annual growth rate from 2024 to 2027 will reach 36%, higher than global peers, demonstrating the company's profit growth potential and industry leadership

Morgan Stanley published a research report stating that, in light of WuXi XDC (02268.HK) disclosing its preliminary results for 2025 and due to a decline in operating profit margins, the bank has lowered its earnings forecasts for 2026 to 2030 by 1% to 2%, and the target price has also been adjusted down by 2%, from HKD 88 to HKD 86.

In addition, the bank predicts that WuXi XDC's adjusted net profit will have a compound annual growth rate of 36% from 2024 to 2027, significantly higher than its global peers, and has given it an "Overweight" rating, optimistic about the company's profit growth and visibility, gross margin expansion potential, and industry leadership position

### Related Stocks

- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [513060.CN - Bosera Hang Seng Health Care ETF(QDII)](https://longbridge.com/en/quote/513060.CN.md)
- [588860.CN - ICBCCS SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588860.CN.md)
- [513120.CN - GF CSI HK Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/513120.CN.md)
- [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md)
- [159992.CN - Yinhua CSI Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159992.CN.md)
- [02268.HK - WUXI XDC](https://longbridge.com/en/quote/02268.HK.md)
- [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md)
- [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md)
- [159615.CN - China Southern Hang Seng Biotech ETF(QDII)](https://longbridge.com/en/quote/159615.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab | CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patien | [Link](https://longbridge.com/en/news/276549711.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |
| Mirxes Completes CADENCE CRC Enrolment for Colorectal Cancer Blood Test Study | Mirxes Holding Company Limited has completed enrolment in the CADENCE CRC study, aimed at validating its blood-based col | [Link](https://longbridge.com/en/news/276577579.md) |
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/en/news/276024005.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/en/news/276016059.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.